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Abstract. The B203.13 monoclonal antibody was developed
by immunizing mice with the B/monocyte biphenotypic cell
line B1b. During normal hematopoiesis B203.13 is expressed
on a fraction of CD34+ cells, while on mature cells it is only
present on B-lymphocytes. We tested this antibody as a marker
of childhood B-acute lymphoblastic leukemia (B-ALL).
Bone marrow aspirates from 139 cases of early B-ALL and
25 controls were studied. About 40% of the B-ALL patients
expressed B203.13. In these patients, B203.13 was constantly
co-expressed with CD10, but never co-expressed with CD20,
contrary to the controls. The CD10+/B203.13+ phenotype was
specific to B-ALL, since CD10+/CD20+ cells from common
acute lymphoblastic leukemia (c-ALL) did not express
B203.13. We concluded that the use of B203.13 in associa-
tion with CD10 and CD20 provides meaningful information
for distinguishing normal residual B-cells from leukemic
B-lymphoblasts and that recurrence of a CD10+/ B203.13+
phenotype after transplantation may be a very early relapse
indicator of early B-acute lymphoblastic leukemia.
Introduction
Acute leukemia has long been recognized as a heterogeneous
disease. To the classical morphological distinction between
acute lymphoblastic and myeloblastic leukemia, a wide array
of disease subsets has been added. These new differentiations
are based on immunophenotype and, more recently, on gene
expression profiling (1). Additionally, differential chromo-
somal and gene abnormalities in leukemia, which may be
reflected in immunophenotypical alterations, define biological
subsets of the disease with therapeutical implications and
prognostic importance (2). For instance, using microarray ex-
pression profiling, B-acute lymphoblastic leukemia (B-ALL)
carrying an MLL gene rearrangement was separated from
other B-ALL (3); similarly, several known leukemia classes
have been described on the basis of gene expression profiles,
with new classes being identified (4). Moreover, a strong
prognostic significance for at least 14 independent prolife-
ration-related genes in the treatment outcome of childhood
ALL has recently been demonstrated (5).
Most genetic studies, however, demonstrate that gene
coding for known diagnostic marker proteins routinely
monitored in B-ALL immunophenotyping are among the best
transcripts for discrimination between leukemia subclasses
(6). This strong correlation between the diagnostic value of
gene expression profiling and that of immunophenotyping,
reinforces the use of flow cytometry detection of leukemia-
associated antigens as a core diagnostic tool for leukemia
diagnosis (7). The classical opinion that acute lymphoblastic
leukemia developed from normal hematopoietic cells
blocked at a particular differentiation stage, has recently been
re-evaluated by the demonstration that leukemic cells often
display immunophenotypic features which are usually
undetectable in normal precursor cells, the so-called aberrant
phenotype. These leukemia-associated phenotypes often
involve cross-lineage antigen expression, asynchronous
antigen expression, or variations in the antigen expression
levels (8-11). In this regard, emphasis has increasingly been
placed on the identification of new monoclonal antibodies
highly capable of discriminating between leukemic and
normal cells (12). Recently we described the expression
pattern of the monoclonal antibody (MoAb) B203.13, that we
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originally generated by immunizing mice with the B myeloid
biphenotypic human cell line B1b (13,14). The antigen
recognized by B203.13 is expressed i) in most peripheral
adult and cord blood B-cells and ii) at minimal density in
mature monocytes, while iii) it is undetectable in granulo-
cytes, T and NK cells, and erythrocytes. In both cord blood
and adult bone marrow, B203.13 MoAb recognizes a surface
marker present on the progenitor cells of several hemato-
poietic lineages, being transiently expressed on CD71+ early
erythroid, CD33+ early myeloid and CD7+ early T-lymphoid
precursors. B203.13 is also expressed on early CD34+/19+
B-lymphoid precursors. We also demonstrated that the
CD34+/B203.13+ subset of human hematopoietic progenitors
is significantly enriched in megakaryocyte progenitors (CFU-
meg) (13). Although not all individuals express detectable
levels of B203.13, its distribution is distinguished from other
known surface molecules, specifically from the polymorphic
HLA-DR and CD1 family of proteins (14).
Given the broad expression of B203.13 on hematopoietic
precursors and its selective persistence in the B-cell lineage,
we were prompted to study the expression of B203.13 in the
bone marrow of young B-ALL patients, for its potential
applications in acute leukemia subsetting and as an early
marker of disease relapse.
Materials and methods
Patients. One hundred and thirty-nine de novo early B-ALL
and 25 pediatric patients affected by non-clonal hematopoietic
disorders were included in this study. The cohort of B-ALL
patients comprised 87 males and 52 females, with a median
age of 9.4 years (range 1-21 years). In all cases, ALL diagnosis
was performed by morphology, cytochemistry, cytogenetics
and molecular genetics. The patients affected by ALL
included in this study derived from a single institution and
were enrolled in the AIEOP 95-2000 protocol according to
the diagnostic guidelines. The morphological classification
was performed by three independent investigators, and a
conclusive diagnosis for every case was reported according
to the FAB criteria.
Immunophenotypic analysis. Immunophenotypic analyses
were performed by multiparameter three- or four-color flow
cytometry using an Epics XL flow cytometer (Beckmann
Coulter, Inc., Miami, FL, USA). Data were acquired using
Expo32 software (Beckmann Coulter). ALL diagnosis was
made using the fluorochrome-conjugated MoAb panel
routinely employed by the AIEOP Reference Laboratory for
Immunophenotypic Studies of the University Hospital of
Padua. Briefly, at least 0.5x106 cells in a final volume of
100 μl were used in each analysis and MoAbs, directly
labelled with fluorescein isothiocyanate (FITC), phyco-
erythrin (PE), or with the fluorochrome tandem conjugates
PE-Texas red (ECD) or PE-cyanine 5 (PECy5), were
combined in each tube according to previously reported
methods (15,16). Isotype-matched negative controls were
used for each MoAb combination.
The following MoAbs were used: CD2, 3, 10, 13, 14, 16,
19, 22, 24, 33, 38, 58, 66c and 135, NG2 and TdT (Beckmann
Coulter), CD5, 8, 11a, 15, 20, 34, and 56 (Becton Dickinson,
San José, CA, USA), CD4, 7, 45, and 65, and HLADR (Caltag
Laboratories, San Francisco, CA, USA), and CD133 (Miltenyi,
Bergisch Gladbach, Germany) (17). FITC-conjugated
B203.13 MoAb was added to the panel of markers described
above. The instrument setup and fluorescence compensation
were optimized daily at the beginning of each procedure by
analyzing the fluorescence of normal T-lymphocytes (always
present in the samples) labeled with the anti-CD4FITC/
CD8PE/CD3ECD/CD45PECy5 four-color combination (6).
An immunological gate including all blast cells was set in
all tube combinations based on the positive expression of
CD19. Specifically, a side scatter dot plot (SSC; logarithmic
amplification) vs. CD19 was used to design the immunological
gate. CD19, instead of the more commonly used CD45 (18),
was chosen for gating since CD45 expression can be low or
negative in a large proportion of B-cell origin ALL. By using
the CD19/log SSC gating strategy, all blast cells were
included, while the percentage of normal B-cells included in
the gate was not significant. In fact, the presence of normal
B-cells was always evaluated using the CD19/34/45 combi-
nation: the percentage of CD19 positive cells with normal
expression of CD45 and negative for CD34 was constantly
lower than 5% in the gated population (15,16). The CD10/
19/20/34 combination was chosen to identify the expression
of B203.13 in the B-cell lineage.
Results and Discussion
It is now well established that immunophenotypic analysis of
neoplastic cells is an invaluable tool for the accurate
diagnosis and classification of acute leukemias, as well as for
the detection of minimal residual disease (MRD) after
therapy and for the early diagnosis of relapse after bone
marrow transplantation. This is essentially due to the fact that
flow cytometry immunophenotyping is more sensitive than
morphology in detecting leukemic cells and is applicable to a
high proportion of leukemias.
Although prognosis in paediatric acute lymphoblastic
leukemias can be assessed quite accurately by PCR and
transcriptional profiling, a close correlation between
molecular methods and flow cytometric immunophenotyping
in the assessment of leukemia subsets and subsequent MRD
and therapy monitoring, has recently been demonstrated
(2,19,20). Therefore, emphasis is increasingly placed on the
identification of new phenotypic markers that might be
relevant for optimizing discrimination between leukemic and
normal cells, and, perhaps more importantly, for MRD
detection and the post-transplantation monitoring of relapse
occurrence.
Recently, we demonstrated that B203.13 was expressed
on CD34+ early myeloerythroid committed progenitors and
on a subset of CD34- cells that included immature progenitors
of most hematopoietic lineages (13,14). B203.13 was also
expressed on committed CD34+/CD19+ precursors, while it
was rapidly down-modulated during further hematopoietic
differentiation. In mature cells it was expressed on B-lym-
phocytes in ~40-50% of healthy individuals. Moreover, it
was recently demonstrated that the expression of CD20 or
CD10 in B-ALL has a prognostic significance in relation to
age (9-11).
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To evaluate B203.13 expression in B-lineage ALL and to
compare the results with normal bone marrow, we tested this
new monoclonal antibody in 139 early B-ALL at diagnosis
stage and in 25 samples collected from children undergoing
bone marrow aspiration for non-lymphoproliferative
disorders (controls). Fifty-four out of 139 early-B-ALL
patients (38.8%) were positive for B203.13. In these patients,
CD19+ bone marrow (BM) cells constantly co-expressed
B203.13 and CD10; whereas B203.13 was never co-
expressed with CD20 (Fig. 1).
Normal bone marrow, on the contrary, showed an opposite
expression pattern: B203.13 was never co-expressed with
CD10, while it was constantly co-expressed with CD20 (11
out of 25 controls expressed B203.13) (Fig. 2). To exclude that
the co-expression of B203.13 with CD10 might be a general
feature of acute leukemias, rather than a specific B-ALL
phenotype, we tested five cases of CD10+/CD20+ common
acute lymphoblastic leukemia (c-ALL), and all resulted
negative for B203.13 (Fig. 3).
As a whole, these data suggest that normal B-lympho-
cytes express B203.13 in the early stages of development
(with a phenotype that is CD19+/CD34+/CD10-/B203.13+);
the expression of B203.13 is then down-regulated at the
pre-B-cell stage (CD19+/CD34+/-/CD10+/CD20-/B203.13-;
CD19+/CD34-/CD10+/CD20+/B203.13-), and finally re-ex-
pressed with CD20 in mature B-cells (CD19+/CD34-/CD10-/
CD20+/B203.13+). On the contrary, the co-expression of
B203.13 with CD10 appears to be a phenotypic characteristic
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Figure 1. Bone marrow flow cytometry immunophenotype of a B203.13+ B-ALL. Virtually all cells were CD34+/B203.13+/CD19+/CD10+, while T-cell
markers like CD7, 4 and 8, and myelomonocytic CD15 and 14 markers, were all negative. CD20 was also always negative. Representative of 54 subjects.
Figure 2. Flow cytometry analysis of B203.13 expression in normal bone
marrow CD19-gated cells. B203.13 is expressed in mature CD10-/CD20+
B-cells, while it is not expressed in CD10+/CD20- B-cell progenitors.
Representative of 11 subjects.
Figure 3. Flow cytometry analysis of B203.13 expression in a case of
c-ALL. CD10+/CD20+ leukemic cells did not express B203.13. Represen-
tative of 5 c-ALL patients.
Figure 4. Proposed scheme of B203.13 expression in the bone marrow of
normal or B-ALL patients. Identification of a leukemic phenotype in
combination with CD10 and 20.
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of B-ALL. The proposed B203.13 expression pattern in
normal vs. B-ALL BM cells is summarized in Fig. 4.
The use of B203.13 in association with CD10 and CD20
provides meaningful information to distinguish normal
residual B-cell from leukemic B-lymphoblasts. Thus, in
B203.13+ ALL it is conceivable that the recurrence of a
CD10+/B203.13+ phenotype after bone marrow transplantation
may be a very early relapse indicator.
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